|
US5686465A
(en)
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5395842A
(en)
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
US5254568A
(en)
|
1990-08-09 |
1993-10-19 |
Council Of Scientific & Industrial Research |
Benzopyrans as antiestrogenic agents
|
|
DE69023906T2
(de)
|
1990-08-09 |
1996-04-11 |
Council Scient Ind Res |
Benzopyrane und Verfahren zu deren Herstellung.
|
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
ATE157869T1
(de)
|
1993-06-24 |
1997-09-15 |
Lilly Co Eli |
Antiöstrogene 2-phenyl-3-aroylbenzothiophene als hypoglykämische mittel
|
|
US5407947A
(en)
*
|
1993-11-05 |
1995-04-18 |
Eli Lilly And Company |
Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
|
|
US5446061A
(en)
|
1993-11-05 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5389646A
(en)
|
1993-12-30 |
1995-02-14 |
Zymogenetics, Inc. |
Methods for treatment and prevention of bone loss using 2,3-benzopyrans
|
|
US5416098A
(en)
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
|
US5637598A
(en)
|
1994-11-18 |
1997-06-10 |
Eli Lilly And Company |
Methods of inhibiting bone loss
|
|
US5446071A
(en)
|
1994-11-18 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5980938A
(en)
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
CA2269974A1
(en)
|
1996-10-28 |
1998-05-07 |
Paul Stanley Bury |
Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
|
|
AU8102498A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
Preparation of diaryl-benzopyrans
|
|
AU8102398A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
(dl)-2,3-diaryl-2h-1-benzopyrans
|
|
CN1275911A
(zh)
|
1997-08-15 |
2000-12-06 |
杜克大学 |
一种预防或治疗雌激素依赖性疾病及失调的方法
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
|
EP1144997A3
(en)
|
1998-03-30 |
2002-08-28 |
The Regents of the University of California |
Methods and compounds for modulating nuclear receptor activity
|
|
CA2323575A1
(en)
|
1998-03-30 |
1999-11-25 |
Regents Of The University Of California |
Methods and compounds for modulating nuclear receptor coactivator binding
|
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US7005428B1
(en)
|
1998-06-11 |
2006-02-28 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
EP1104414B1
(en)
|
1998-08-14 |
2003-02-12 |
Schering Corporation |
Enantioselective synthesis
|
|
US6262270B1
(en)
*
|
1998-08-14 |
2001-07-17 |
Schering Corporation |
Enantioselective synthesis
|
|
AU2156800A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Oral antiestrogen pharmaceutical composition
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
DE19916419B4
(de)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
|
|
JP4790178B2
(ja)
|
1999-07-06 |
2011-10-12 |
アンドルシェルシュ・インコーポレイテッド |
体重増加の処置方法および／または抑制方法
|
|
AU7896100A
(en)
|
1999-10-14 |
2001-04-23 |
Endorecherche Inc. |
Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
EP1251855A1
(en)
|
2000-01-28 |
2002-10-30 |
Endorecherche, Inc. |
Selective estrogen receptor modulators in combination with estrogens
|
|
WO2001063292A2
(en)
|
2000-02-22 |
2001-08-30 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of het, a novel modulator of estrogen action
|
|
DE10013782A1
(de)
*
|
2000-03-15 |
2001-10-18 |
Schering Ag |
4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6528681B2
(en)
|
2000-04-05 |
2003-03-04 |
Bristol-Meyers Squibb Pharma Company |
Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US8119138B2
(en)
|
2000-05-10 |
2012-02-21 |
Signe Biopharma Inc. |
Anti-estrogen and immune modulator combinations for treating breast cancer
|
|
US7863011B2
(en)
|
2000-05-10 |
2011-01-04 |
Signe Biopharma, Inc. |
Screening method for predicting susceptibility to breast cancer
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
ATE278421T1
(de)
|
2000-08-11 |
2004-10-15 |
Wyeth Corp |
Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
|
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
|
JP2004508334A
(ja)
|
2000-09-08 |
2004-03-18 |
フアルマシア・イタリア・エツセ・ピー・アー |
化学予防剤としてのエクセメスタン
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
HUP0301276A2
(hu)
|
2000-10-06 |
2003-11-28 |
Biomedicines, Inc. |
Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
EP1328522A2
(en)
|
2000-10-19 |
2003-07-23 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
EE200300153A
(et)
|
2000-10-19 |
2003-06-16 |
Merck & Co., Inc. |
Östrogeeni retseptori modulaatorid, farmatseutiline kompositsioon ja selle valmistamismeetod
|
|
EP1377298B1
(en)
|
2001-01-26 |
2006-08-30 |
Pfizer Italia S.r.l. |
Exemestane for treating hormono-dependent disorders
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
US20040082557A1
(en)
|
2001-01-26 |
2004-04-29 |
Wajszczuk Charles Paul |
Methods for treating estrogen-dependent disorders
|
|
GB2374412A
(en)
|
2001-04-11 |
2002-10-16 |
Karobio Ab |
Hypertension treatment and assay
|
|
EP1417169A2
(en)
|
2001-08-11 |
2004-05-12 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
EP1429779A2
(en)
|
2001-09-21 |
2004-06-23 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
|
JP4490689B2
(ja)
|
2001-10-03 |
2010-06-30 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
|
|
PL370080A1
(en)
|
2001-10-10 |
2005-05-16 |
Pharmacia Italia Spa |
Methods for preventing and treating bone loss with steroid compounds
|
|
WO2003034987A2
(en)
|
2001-10-19 |
2003-05-01 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
US7105679B2
(en)
*
|
2001-12-19 |
2006-09-12 |
Kanojia Ramesh M |
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
|
|
IL162295A0
(en)
*
|
2001-12-19 |
2005-11-20 |
Ortho Mcneil Pharm Inc |
Tetracyclic heterocompounds as estrogen receptor modulators
|
|
WO2003063859A1
(en)
|
2002-01-14 |
2003-08-07 |
Nordic Bioscience A/S |
Suppression of cartilage degradation via the estrogen receptor
|
|
WO2003070253A1
(en)
|
2002-02-21 |
2003-08-28 |
Pantarhei Bioscience B.V. |
Estrogenic component for treating decreased libido in women
|
|
US20050118600A1
(en)
|
2002-03-13 |
2005-06-02 |
Yuko Aoki |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
NZ534946A
(en)
|
2002-03-13 |
2007-05-31 |
Merck & Co Inc |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
|
US20030225132A1
(en)
|
2002-04-11 |
2003-12-04 |
Dininno Frank P. |
Estrogen receptor modulators
|
|
ATE481397T1
(de)
|
2002-04-24 |
2010-10-15 |
Merck Sharp & Dohme |
Modulatoren des östrogenrezeptors
|
|
WO2003092588A2
(en)
|
2002-04-30 |
2003-11-13 |
Merck & Co., Inc. |
4-azasteroid derivatives as androgen receptor modulators
|
|
AU2003247608A1
(en)
|
2002-06-25 |
2004-01-06 |
Wyeth |
Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
|
|
JP2005535623A
(ja)
|
2002-06-25 |
2005-11-24 |
ワイス |
ホルモン関連症状の治療における、チオ−オキシインドール誘導体の使用
|
|
WO2004041277A1
(en)
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
WO2004091488A2
(en)
|
2003-04-14 |
2004-10-28 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
EP1622567B1
(en)
|
2003-05-07 |
2013-07-24 |
Merck Sharp & Dohme Corp. |
Androgen receptor modulators and methods of use thereof
|
|
PT1622630E
(pt)
|
2003-05-07 |
2012-10-11 |
Osteologix As |
Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
EP1641761A4
(en)
|
2003-06-30 |
2008-05-14 |
Merck & Co Inc |
17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
|
|
EP1641535A4
(en)
|
2003-06-30 |
2008-05-14 |
Merck & Co Inc |
17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
|
|
AU2004255749B2
(en)
|
2003-06-30 |
2008-12-18 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
WO2005009949A2
(en)
|
2003-06-30 |
2005-02-03 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
EP1670483A4
(en)
|
2003-09-10 |
2010-02-17 |
Merck & Co Inc |
17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
|
|
EP1663228A4
(en)
|
2003-09-10 |
2010-10-06 |
Merck Sharp & Dohme |
17-heterocyclic 4-azasteroid derivatives as androgen receptor modules
|
|
EP1692127B1
(en)
|
2003-10-08 |
2008-07-02 |
Smithkline Beecham Corporation |
Triphenylethylene compounds as selective estrogen receptor modulators
|
|
JP2007509962A
(ja)
|
2003-10-31 |
2007-04-19 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体調節剤としての２１−複素環−４−アザステロイド誘導体
|
|
WO2005073190A1
(en)
|
2004-01-29 |
2005-08-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
WO2005123130A2
(en)
|
2004-06-17 |
2005-12-29 |
Osteologix A/S |
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
|
|
JP2008502609A
(ja)
|
2004-06-17 |
2008-01-31 |
オステオロジックス エイ／エス |
リウマチおよび関節性疾患の治療改善方法
|
|
AU2005279178A1
(en)
|
2004-09-03 |
2006-03-09 |
Hormos Medical Ltd |
Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
|
|
CN106038572A
(zh)
|
2004-10-20 |
2016-10-26 |
恩多研究公司 |
性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
|
|
WO2006084937A1
(en)
|
2005-02-14 |
2006-08-17 |
Leskelae Hannu-Ville |
Method for diagnosing and treating women with increased response to hormonal replacement therapy
|
|
US20070078114A1
(en)
|
2005-09-02 |
2007-04-05 |
Myriad Genetics, Incorporated |
Combination therapy for alzheimer's disease and other diseases
|
|
WO2007098090A2
(en)
|
2006-02-17 |
2007-08-30 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
|
|
US20080268041A1
(en)
|
2007-04-23 |
2008-10-30 |
Jens Hoffmann |
Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
|
|
DE102007026877A1
(de)
|
2007-06-08 |
2008-12-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
|
|
US20110104121A1
(en)
|
2008-05-21 |
2011-05-05 |
Wira Charles R |
Female Reproductive Tract and Anal Prophylaxes
|
|
WO2010107474A1
(en)
|
2009-03-16 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Antiestrogens for breast cancer therapy
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
EP3205648A1
(en)
|
2010-06-10 |
2017-08-16 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
EP2791132A4
(en)
|
2011-12-14 |
2015-08-05 |
Seragon Pharmaceuticals Inc |
ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
BR112014014767A2
(pt)
|
2011-12-16 |
2017-06-13 |
Olema Pharmaceuticals Inc |
novos compostos de benzopirano, composições e usos dos mesmos
|